Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Inclusion Criteria:

Diagnosis of epithelial ovarian cancer
Must have measurable disease by CT or MRI scan
Must have relapsed as defined by CA-125 or radiologically within 6 months or more of completion of first- or second-line platinum chemotherapy
Must have been treated with surgery and be a candidate for repeat carboplatin therapy
Must have a normal cardiac ejection fraction at baseline

Exclusion Criteria:

Subjects who never responded to first- or second-line platinum-based chemotherapy or whose relapse occurs <6 months from the last platinum therapy
Subjects who have received other therapy to treat their ovarian cancer since last relapse
Known central nervous system tumor involvement
Evidence of other active invasive malignancy
Clinically significant heart disease
Known allergic reaction to a prior monoclonal antibody therapy or have any documented HAHA
Previous treatment with MORAb 003 (farletuzumab)
Previous treatment with anthracyclines
Clinical contraindications to use PLD